{
    "doi": "https://doi.org/10.1182/blood.V114.22.3343.3343",
    "start_url": "https://ashpublications.org/blood/search-results?sort=Date+-+Oldest+First&f_ArticleTypeDisplayName=Meeting+Report&fl_SiteID=1000001&page=1606",
    "start_url_page_num": 1606,
    "is_scraped": "1",
    "article_title": "Incidence and Risk Factors for Lower Alimentary Tract Mucositis (neutropenic enterocolitis) Following 1528 Courses of Chemotherapy in a Homogenous Population of Myeloma Patients: Clinical and Research Implications. ",
    "article_date": "November 20, 2009",
    "session_type": "Clinical Care - Transplantation Regimen Toxicities and Engraftment Poster III",
    "topics": [
        "chemotherapy regimen",
        "gastrointestinal tract",
        "mucositis",
        "multiple myeloma",
        "neutropenic enterocolitis",
        "transplantation",
        "serum albumin",
        "autologous stem cell transplant",
        "creatinine clearance",
        "melphalan"
    ],
    "author_names": [
        "Somashekar G Krishna, MD, MPH",
        "Zhao Weizhi",
        "Kavya Krishna, MD",
        "Monica Grazziutti, MD",
        "Bart Barlogie, MD, PhD",
        "Elias Anaissie, MD"
    ],
    "author_affiliations": [
        [
            "Department of Gastroenterology, Univ of Arkansas for Medical Sciences, Little Rock, AR, USA, "
        ],
        [
            "Myeloma Institute for Research and Therapy, University of Arkansas for Medical Sciences, Little Rock, AR, USA, "
        ],
        [
            "Department of Internal Medicine, University of Arkansas for Medical Sciences, Little Rock, AR, USA"
        ],
        [
            "Myeloma Institute for Research and Therapy, University of Arkansas for Medical Sciences, Little Rock, AR, USA, "
        ],
        [
            "Myeloma Institute for Research and Therapy, University of Arkansas for Medical Sciences, Little Rock, AR, USA, "
        ],
        [
            "Myeloma Institute for Research and Therapy, University of Arkansas for Medical Sciences, Little Rock, AR, USA, "
        ]
    ],
    "first_author_latitude": "34.747959",
    "first_author_longitude": "-92.31936309999999",
    "abstract_text": "Abstract 3343 Poster Board III-231 Background: lower alimentary tract mucositis (L-ATM), also known as neutropenic enterocolitis, is a complication of chemotherapy with high mortality rates. The incidence, risk factors and mortality of L-ATM remain unknown. Purpose: To determine the incidence, risk factors and mortality of L-ATM in a homogeneous population of patients with multiple myeloma. Patients and Methods: 303 newly diagnosed myeloma patients (2004 - 2007) were enrolled in a protocol consisting of induction chemotherapy, tandem melphalan-based autologous stem-cell transplantation (ASCT) and consolidation. Lower -ATM was defined as grade II-IV enteritis/colitis occurring during neutropenia. All data were collected prospectively. The analysis of risk factors included body surface area (BSA), creatinine clearance (CrCl), serum albumin and other pretreatment variables. Multiple logistic regression model was used to compute adjusted odds ratio (OR) and 95% confidence intervals (CI). Results: 47 patients (15.5%) developed L-ATM during 1528 chemotherapy cycles (including 536 ASCT). BSA < 2 m 2 (OR 2.853; 95% CI 1.232, 6.607; p = 0.0144) and CrCl <60ml/min (OR 3.089; 95% CI 1.176, 8.114; p = 0.0221) increased the risk for L-ATM while higher serum albumin was protective (OR 0.695; 95% CI 0.517, 0.936; p = 0.0167). No L-ATM-related death was observed. Conclusions: Lower-ATM is not uncommon among myeloma patients undergoing multiple cycles of chemotherapy but does not contribute to mortality. The risk for L-ATM is determined by lower values of BSA, renal function and serum albumin. These findings have significant implications for the study and management of L-ATM in patients undergoing chemotherapy. Multivariate analysis: Risk factors for lower alimentary tract mucositis (L-ATM)  Treatment stage . Variables . Control group\u00a4 . L-ATM . . . Baseline . . N (%) . N (%) . OR (95% CI) . p - value .  ALB (g/dL), unit = 0.5 39.97 \u00b1 5.12 37.79 \u00b1 6.01 0.695 (0.517, 0.936) 0.0167  BSA (<2.0 m 2 ) 132 (61.97) 39 (82.98) 2.853 (1.232, 6.607) 0.0144  e-CrCl (<60 ml/min) 31 (14.55) 13 (27.66) 1.534 (0.697, 3.375) 0.2880 Induction cycle 2        ALB (g/dL), unit = 0.5 36.86 \u00b1 4.05 33.00 \u00b1 3.22 0.347 (0.129, 0.934) 0.0362  BSA (<2.0 m 2 ) 186 (67.39) 3 (50.00) 0.567 (0.105, 3.073) 0.5106  e-CrCl (<60 ml/min) 34 (12.32) 1 (16.67) 1.469 (0.153, 14.09) 0.7390 Transplant 1        ALB (g/dL), unit = 0.5 38.60 \u00b1 4.11 35.53 \u00b1 3.16 0.462 (0.248, 0.863) 0.0154  BSA (<2.0 m 2 ) 165 (64.71) 15 (88.24) 4.130 (0.874, 19.53) 0.0735  e-CrCl (<60 ml/min) 21 (8.24) 6 (35.29) 3.688 (1.093, 12.44) 0.0354 Transplant 2        ALB (g/dL), unit = 0.5 38.65 \u00b1 4.27 36.96 \u00b1 4.45 0.748 (0.470, 1.190) 0.2207  BSA (<2.0 m 2 ) 139 (64.65) 24 (92.31) 5.906 (1.339, 26.05) 0.0190  e-CrCl (<60 ml/min) 19 (8.84) 5 (19.23) 1.586 (0.505, 4.987) 0.4299 Transplants 1 +2(N=285)        ALB (g/dL), unit = 0.5 38.79 \u00b1 4.23 36.41 \u00b1 2.88 0.489 (0.304, 0.787) 0.0032  BSA (<2.0 m 2 ) 141 (62.39) 33 (89.19) 5.433 (1.779, 16.59) 0.0030  e-CrCl (<60 ml/min) 16 (7.08) 10 (27.03) 3.089 (1.176, 8.114) 0.0221 Consolidation cycles 1+2        ALB (g/dL), unit = 0.5 38.10 \u00b1 3.78 37.86 \u00b1 4.06 0.899 (0.367, 2.201) 0.8151  BSA (<2.0 m 2 ) 130 (65.99) 7 (100.0) . .  e-CrCl (<60 ml/min) 15 (7.61) 2 (28.57) 3.162 (0.571, 17.51) 0.1874 Treatment stage . Variables . Control group\u00a4 . L-ATM . . . Baseline . . N (%) . N (%) . OR (95% CI) . p - value .  ALB (g/dL), unit = 0.5 39.97 \u00b1 5.12 37.79 \u00b1 6.01 0.695 (0.517, 0.936) 0.0167  BSA (<2.0 m 2 ) 132 (61.97) 39 (82.98) 2.853 (1.232, 6.607) 0.0144  e-CrCl (<60 ml/min) 31 (14.55) 13 (27.66) 1.534 (0.697, 3.375) 0.2880 Induction cycle 2        ALB (g/dL), unit = 0.5 36.86 \u00b1 4.05 33.00 \u00b1 3.22 0.347 (0.129, 0.934) 0.0362  BSA (<2.0 m 2 ) 186 (67.39) 3 (50.00) 0.567 (0.105, 3.073) 0.5106  e-CrCl (<60 ml/min) 34 (12.32) 1 (16.67) 1.469 (0.153, 14.09) 0.7390 Transplant 1        ALB (g/dL), unit = 0.5 38.60 \u00b1 4.11 35.53 \u00b1 3.16 0.462 (0.248, 0.863) 0.0154  BSA (<2.0 m 2 ) 165 (64.71) 15 (88.24) 4.130 (0.874, 19.53) 0.0735  e-CrCl (<60 ml/min) 21 (8.24) 6 (35.29) 3.688 (1.093, 12.44) 0.0354 Transplant 2        ALB (g/dL), unit = 0.5 38.65 \u00b1 4.27 36.96 \u00b1 4.45 0.748 (0.470, 1.190) 0.2207  BSA (<2.0 m 2 ) 139 (64.65) 24 (92.31) 5.906 (1.339, 26.05) 0.0190  e-CrCl (<60 ml/min) 19 (8.84) 5 (19.23) 1.586 (0.505, 4.987) 0.4299 Transplants 1 +2(N=285)        ALB (g/dL), unit = 0.5 38.79 \u00b1 4.23 36.41 \u00b1 2.88 0.489 (0.304, 0.787) 0.0032  BSA (<2.0 m 2 ) 141 (62.39) 33 (89.19) 5.433 (1.779, 16.59) 0.0030  e-CrCl (<60 ml/min) 16 (7.08) 10 (27.03) 3.089 (1.176, 8.114) 0.0221 Consolidation cycles 1+2        ALB (g/dL), unit = 0.5 38.10 \u00b1 3.78 37.86 \u00b1 4.06 0.899 (0.367, 2.201) 0.8151  BSA (<2.0 m 2 ) 130 (65.99) 7 (100.0) . .  e-CrCl (<60 ml/min) 15 (7.61) 2 (28.57) 3.162 (0.571, 17.51) 0.1874 View Large Pre-treatment characteristics of 303 myeloma patients: Lower alimentary tract mucositis (LATM) vs. controls  . All patients N=303 . Control group \u00a4 N=213 . LATM N=47 . P-value \u03bc . CMV IgG positive , N (%) 190 (62.7) 139 (65.3) 25 (53.2) 0.1345 Body Surface Area (BSA) \u2020  Median, m 2  1.88 1.9 1.80 0.0253 Range, m 2  1.41-2.56 1.41 - 2.56 1.48 - 2.21  < 2.01 m 2  201 (66.3) 132 (62.0) 39 (83.0) 0.0063 >= 2.01 m 2  102 (33.7) 81 (38.0) 8 (17.0)  Melphalan dose for transplant cycles  Transplant 1 N=285 N=255 N=17  Median, mg/kg 4.49 4.42 4.58 0.2329 Range, mg/kg 2.00-6.82 2.00 - 6.53 3.10 - 6.82  Transplant 2  N=251 N=215 N=26  Median, mg/kg 4.50 4.47 4.94 0.0250 Range, mg/kg 2.41-6.58 2.41 - 6.58 3.05 - 6.11  Serum Albumin  Median, g/dL 4 4 3.9 0.0207 Range, g/dL 2.1-5.3 2.5 \u2013 5.3 2.1 - 4.9  Estimated creatinine clearance  Median, ml/min 93.8 95.2 87.7 0.1463 Range, ml/min 9.0 -245.7 9.0 - 245.7 9.9 - 172.4  <60 ml/min 49 (16.2) 31 (14.6) 13 (27.7) 0.0505 \u226560 ml/min 254 (83.8) 182 (85.5) 34 (72.3)  . All patients N=303 . Control group \u00a4 N=213 . LATM N=47 . P-value \u03bc . CMV IgG positive , N (%) 190 (62.7) 139 (65.3) 25 (53.2) 0.1345 Body Surface Area (BSA) \u2020  Median, m 2  1.88 1.9 1.80 0.0253 Range, m 2  1.41-2.56 1.41 - 2.56 1.48 - 2.21  < 2.01 m 2  201 (66.3) 132 (62.0) 39 (83.0) 0.0063 >= 2.01 m 2  102 (33.7) 81 (38.0) 8 (17.0)  Melphalan dose for transplant cycles  Transplant 1 N=285 N=255 N=17  Median, mg/kg 4.49 4.42 4.58 0.2329 Range, mg/kg 2.00-6.82 2.00 - 6.53 3.10 - 6.82  Transplant 2  N=251 N=215 N=26  Median, mg/kg 4.50 4.47 4.94 0.0250 Range, mg/kg 2.41-6.58 2.41 - 6.58 3.05 - 6.11  Serum Albumin  Median, g/dL 4 4 3.9 0.0207 Range, g/dL 2.1-5.3 2.5 \u2013 5.3 2.1 - 4.9  Estimated creatinine clearance  Median, ml/min 93.8 95.2 87.7 0.1463 Range, ml/min 9.0 -245.7 9.0 - 245.7 9.9 - 172.4  <60 ml/min 49 (16.2) 31 (14.6) 13 (27.7) 0.0505 \u226560 ml/min 254 (83.8) 182 (85.5) 34 (72.3)  Control group \u00a4: patients who did not develop enterocolitis (neutropenic or Clostridium difficile colitis (CDI)) during any cycle of therapy. 43 patients with CDI were excluded from analysis. \u2020 BSA cut off at 2 m2 is based on the highest tertile of the control group \u03bc Fisher's exact test used for categorical variables, Wilcoxon rank sum test for continuous variables. View Large Disclosures: No relevant conflicts of interest to declare."
}